novavax
announces
vaccine
manufacturing
agreement
serum
institute
india
increasing
novavax
global
production
capacity
billion
doses
annually
serum
institute
india
manufacture
billion
doses
increases
global
manufacturing
capacity
billion
annualized
doses
full
capacity
agreement
expands
novavax
partnership
world
largest
vaccine
developer
increase
global
delivery
gaithersburg
globe
newswire
novavax
nasdaq
nvax
biotechnology
company
developing
vaccines
serious
infectious
diseases
today
announced
amendment
existing
agreement
serum
institute
india
private
limited
siipl
siipl
also
manufacture
antigen
component
novavax
vaccine
candidate
agreement
novavax
increases
manufacturing
capacity
two
billion
doses
annually
planned
capacity
brought
online
stable
prefusion
protein
made
using
novavax
recombinant
protein
nanoparticle
technology
includes
novavax
proprietary
adjuvant
today
agreement
serum
institute
enhances
novavax
commitment
equitable
global
delivery
vaccine
arrangement
put
place
global
supply
chain
includes
recently
acquired
praha
vaccines
partnerships
leading
biologics
manufacturers
enabling
production
three
continents
said
stanley
erck
president
chief
executive
officer
novavax
continue
work
extraordinary
urgency
develop
vaccine
phase
clinical
trials
anticipate
starting
phase
efficacy
trials
around
world
coming
agreement
siipl
augments
global
supply
chain
deliver
two
billion
doses
annually
antigen
component
manufactured
novavax
cz
bohumil
czech
republic
formerly
praha
vaccines
well
following
partnered
manufacturing
sites
biofabri
spain
fujifilm
diosynth
biotechnologies
fdb
north
carolina
texas
united
states
fdb
united
kingdom
siipl
india
sk
bioscience
republic
korea
takeda
pharmaceutical
company
limited
japan
novavax
adjuvant
manufactured
novavax
ab
uppsala
sweden
following
partnered
manufacturing
sites
agc
biologics
united
states
denmark
polypeptide
group
manufacture
two
key
intermediaries
used
united
states
sweden
signing
manufacturing
agreement
novavax
another
great
milestone
companies
strengthen
existing
relationship
siipl
expertise
manufacture
help
ensure
supply
vaccine
said
adar
poonawalla
chief
executive
officer
serum
institute
india
vaccine
candidate
engineered
genetic
sequence
virus
causes
disease
created
using
novavax
recombinant
nanoparticle
technology
generate
antigen
derived
coronavirus
spike
protein
contains
novavax
patented
adjuvant
enhance
immune
response
stimulate
high
levels
neutralizing
antibodies
preclinical
trials
demonstrated
indication
antibodies
block
binding
spike
protein
receptors
targeted
virus
critical
aspect
effective
vaccine
protection
phase
portion
phase
clinical
trial
generally
elicited
robust
antibody
responses
numerically
superior
seen
human
convalescent
sera
phase
clinical
trials
began
august
novavax
secured
billion
funding
global
coronavirus
vaccine
program
including
million
funding
coalition
epidemic
preparedness
innovations
cepi
novavax
patented
adjuvant
demonstrated
potent
effect
stimulating
entry
cells
injection
site
enhancing
antigen
presentation
local
lymph
nodes
boosting
immune
response
novavax
novavax
nasdaq
nvax
biotechnology
company
promotes
improved
health
globally
discovery
development
commercialization
innovative
vaccines
prevent
serious
infectious
diseases
novavax
undergoing
clinical
trials
vaccine
candidate
virus
causes
quadrivalent
influenza
nanoparticle
vaccine
met
primary
objectives
pivotal
phase
clinical
trial
older
adults
vaccine
candidates
incorporate
novavax
proprietary
adjuvant
order
enhance
immune
response
stimulate
high
levels
neutralizing
antibodies
novavax
leading
innovator
recombinant
vaccines
proprietary
recombinant
technology
platform
combines
power
speed
genetic
engineering
efficiently
produce
highly
immunogenic
nanoparticles
order
address
urgent
global
health
needs
information
visit
connect
us
twitter
linkedin
serum
institute
india
serum
institute
india
pvt
founded
cyrus
poonawalla
mission
manufacturing
serum
world
largest
vaccine
manufacturer
number
doses
produced
sold
globally
billion
doses
estimated
children
world
receive
least
one
vaccine
manufactured
serum
institute
vaccines
manufactured
serum
accredited
world
health
organization
geneva
used
approximately
countries
across
globe
serum
ranked
india
biotechnology
company
manufacturing
highly
specialized
lifesaving
biologics
like
vaccines
using
cutting
edge
genetic
technologies
antisera
medical
specialties
philanthropic
philosophy
serum
continues
work
newer
vaccines
biologicals
learn
serum
institute
india
https
cepi
cepi
innovative
partnership
public
private
philanthropic
civil
society
organizations
launched
davos
develop
vaccines
stop
future
epidemics
cepi
moved
great
urgency
coordination
response
emergence
cepi
initiated
partnerships
develop
vaccines
novel
coronavirus
programs
leverage
rapid
response
platforms
already
supported
cepi
well
new
partnerships
aim
advance
vaccine
candidates
clinical
testing
quickly
possible
emergence
cepi
priority
diseases
included
ebola
virus
lassa
virus
middle
east
respiratory
syndrome
coronavirus
nipah
virus
rift
valley
fever
chikungunya
virus
cepi
also
invested
platform
technologies
used
rapid
vaccine
immunoprophylactic
development
unknown
pathogens
disease
x
novavax
statements
statements
herein
relating
future
novavax
ongoing
development
vaccine
adjuvant
products
statements
novavax
cautions
statements
subject
numerous
risks
uncertainties
could
cause
actual
results
differ
materially
expressed
implied
statements
risks
uncertainties
include
identified
heading
risk
factors
novavax
annual
report
form
year
ended
december
quarterly
report
form
period
ended
june
filed
securities
exchange
commission
sec
caution
investors
place
considerable
reliance
statements
contained
press
release
encouraged
read
filings
sec
available
discussion
risks
uncertainties
statements
press
release
speak
date
document
undertake
obligation
update
revise
statements
business
subject
substantial
risks
uncertainties
including
referenced
investors
potential
investors
others
give
careful
consideration
risks
uncertainties
contacts
novavax
investors
silvia
taylor
erika
trahan
ir
